SuperworthValion Bio EPS VBIO
Diluted earnings per share by quarter and over the last twelve months, from 2021.
- Last 12 months, to Jun 30, 2025
- −$203.75
- Latest quarter, Q2 FY25
- −$54.75
- Fiscal year 2024
- −$649.00
Valion Bio's earnings per share was −$203.75 over the twelve months to Jun 30, 2025.
In its latest quarter, Q2 FY25, it was −$54.75.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2024 | −$649.00 | n/a |
| FY2022 | −$2631.00 | n/a |
| FY2021 | −$6250.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY25 | −$54.75 | n/a | −$203.75 | |
| Q1 FY25 | −$63.00 | n/a | −$283.25 | |
| Q4 FY24 | −$80.25 | n/a | −$649.00 | |
| Q3 FY24 | −$5.75 | n/a | n/a | |
| Q2 FY24 | −$134.25 | n/a | n/a | |
| Q1 FY24 | −$428.75 | n/a | n/a | |
| Q3 FY23 | −$37.00 | n/a | −$1060.00 | |
| Q2 FY23 | −$179.00 | n/a | −$1698.00 | |
| Q1 FY23 | −$263.00 | n/a | −$2319.00 | |
| Q4 FY22 | −$581.00 | n/a | −$2631.00 | |
| Q3 FY22 | −$675.00 | n/a | −$3450.00 | |
| Q2 FY22 | −$800.00 | n/a | −$5025.00 |
Against its peers
Companies in Drug Manufacturers - General nearest Valion Bio's size, closest first, today.
| Company | EPS, 12 months |
|---|---|
| VBIOValion Bio | n/m |
| NXTSNexentis Technologies | n/m |
| LABTLakewood-Amedex Biotherapeutics | n/m |
| JAGXJaguar Health | −$6051.75 |
| DCOYDecoy Therapeutics | n/m |
| SBFMSunshine Biopharma | n/m |
| ARTLArtelo Biosciences | −$207.09 |
| LNAILunai Bioworks | n/m |
| GNPXGenprex | n/m |
| GOVXGeoVax Labs | n/m |
| ONCOOnconetix | −$199.38 |
| Peer median | −$207.09 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Valion Bio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.